Global Depression Screening Market, By Disease Type (Anxiety, Depression, Mood Disorders, Bipolar Disorders, Eating Disorders, Psychotic Disorders, Others), Diagnosis (Psychological Test, Depression Screening Tests, Lab Tests, Others), Treatment (Medication, Deep Brain Stimulation, Brain-Stimulation Treatments,) End User (Hospitals and Clinics, Academic Institutes, Medical Research Centers, Others) - Industry Trends and Forecast to 2030.
Depression Screening Market Analysis and Size
Depression screening, also known as the depression test, is largely used to find out if the patient is clinically depressed. It is a type of a common illness, but depression varies from regular feelings of sadness and can also affect the thinking process and behavior of a person.
The increasing prevalence of mental disorders across the globe is among the significant factors fueling the growth and demand for the global depression screening market. In addition, the easy availability of advanced diagnostic and treatment methods and the rising number of patients who have mental illness and related disorders are also contributing to the growth in the global market over the forecast period of 2023 to 2030 Also, the rapidly increasing funds in research activities and rapidly changing healthcare sector are also lifting the growth of the market. Furthermore, the increasing per capita disposable income is also one of the significant factors flourishing the growth of the global depression screening market. The rising number of patients who have mental illness and related disorders will also make sure high industry growth over the forecast period.
Data Bridge Market Research analyses that the global depression screening market was valued at USD 10,624.91 million in 2022 and is further estimated to reach USD 15,829.87 million by 2030, and is expected to grow at a CAGR of 5.11% during the forecast period of 2023 to 2030. The Data Bridge Market Research team curated market report includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Depression Screening Market Scope and Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2023 to 2030
|
|
Base Year
|
2022
|
|
Historic Year
|
2021 (Customizable to 2015 - 2020)
|
|
Quantitative Units
|
Revenue in USD Million
|
|
Segments Covered
|
By Disease Type (Anxiety, Depression, Mood Disorders, Bipolar Disorders, Eating Disorders, Psychotic Disorders, Others), Diagnosis (Psychological Test, Depression Screening Tests, Lab Tests, Others), Treatment (Medication, Deep Brain Stimulation, Brain-Stimulation Treatments,) End User (Hospitals and Clinics, Academic Institutes, Medical Research Centres, Others)
|
|
Countries Covered
|
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa(MEA), Brazil, Argentina and Rest of South America as part of South America.
|
|
Market Players Covered
|
Johnson & Johnson Services Inc. (U.S.), AstraZeneca (U.K.), Bristol-Myers Squibb Company (U.S.), Lilly (U.S.) , F. Hoffmann-La Roche Ltd., (Switzerland), Novartis AG (Switzerland), Otsuka Holdings Co.,Ltd. (Japan), Pfizer Inc.(U.S.), GSK plc (U.K.), Janssen Global Services LLC, (Belgium), Meiji Holdings Co., Ltd (Japan), Ltd., Abbott (U.S.), Jazz Pharmaceuticals Inc. (Ireland), AbbVie Inc. (U.S.), 3M (U.S.), Acadia Pharmaceuticals Inc.(U.S.), Medtronic (Ireland), Bausch Health Companies Inc.(Canada), and Merck KGaA (Germany) among other
|
|
Market Opportunities
|
|
Market Definition
The market includes both traditional screening methods, such as questionnaires and interviews, and technologically advanced solutions, such as digital platforms, mobile applications, and wearable device that enable convenient remote screening. It includes various screening tools, techniques, and services to identify and assess symptoms of depression so that health professionals can make an accurate diagnosis and develop an appropriate treatment plan increase. The global depression screening market serves individuals seeking mental health assessment, healthcare providers, mental health organizations, and other stakeholders involved in the diagnosis and management of depression. It plays a crucial role in early identification, intervention, and prevention of depression, aiming to improve mental health outcomes and enhance overall well-being.
Global Depression Screening Market Dynamics
Drivers
- Increasing Prevalence of Depression
The rising prevalence of depression across the globe is the primary driver for the growth of the global depression screening market. Stress, lifestyle changes, and social pressure have contributed to the increased prevalence of depression, creating a need for effective screening methods, which is expected to drive market growth.
- Rising Awareness and Mental Health Advocacy
Awareness of mental health issues, including depression, is growing around the world. An increasing number of organizations, government initiatives, and celebrity advocacy have reduced the stigma associated with mental health and encouraged more people to seek testing and treatment options, which is expected to drive the market growth
- Technological Advancements in Screening Tools
The growing advancement in technology has led to the development of innovative screening tools and solutions for depression. Digital platforms, mobile apps, and mobile devices equipped with depression screening features have made it easier and easier to assess people's mental health status, which has fuelled market growth.
Opportunities
- Growing Adoption of Telehealth and Remote Screening
The increasing adoption of telehealth services provides an opportunity for remote depression screening. Virtual consultations and digital screening tools enable individuals to access screening services from the comfort of their homes, eliminating geographical barriers and improving access to mental health care.
- Increasing Technological Advancements
- Continued integrating artificial intelligence technologies, such as machine learning algorithms, into depression screening tools offers opportunities for more accurate and efficient assessments. Exam platforms powered by AI can analyze large data sets, identify patterns and deliver personalized exam results, improving the overall exam process, which helps to create an opportunity for the market growth.
Restraint
- Limited Awareness and Stigma in Certain Regions
Although mental health awareness is growing worldwide, there are still areas where awareness and stigma around mental health issues, such as depression, are still limited. A lack of awareness may hinder the adoption of depression control services in these regions, thereby hindering market growth.
Challenges
- Lack of Quality Assurance and Standardization
Ensuring the quality and standardization of depression screening tools and methods across regions and health facilities can be challenging. To maintain the reliability of depression screening programs, it is important to develop uniform screening guidelines and protocols and establish criteria for accuracy and reliability.
This global depression screening market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the global depression screening market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Recent Developments
- In April 2021, the company received breakthrough device designation from the FDA for its digital diagnostic and therapeutic platform for autism spectrum disorder (ASD) and comorbid behavioral health conditions like depression.
- In September 2020, Pear Therapeutics received FDA clearance for its digital therapeutic called reSET-O. This prescription digital therapeutic is designed to treat opioid use disorder with a co-occurring moderate-to-severe depressive disorder.
Global Depression Screening Market Scope
The global depression screening market is segmented into five notable segments based on disease type, diagnosis, treatment, and end user. The growth among segments helps you analyze niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.
Disease Type
- Anxiety
- Mood disorders
- Depression
- Bipolar disorders
- Psychotic disorders
- Eating disorders
- Others
Diagnosis
- Psychological test
- Lab tests
- Depression screening tests
- Others
Treatment
- Medication
- Brain-stimulation treatments
- Deep brain stimulation
End User
- Hospitals and clinics
- Medical research centers
- Academic institutes
- Others
Global Depression Screening Market Regional Analysis/Insights
The global depression screening market is analyzed, and market size insights and trends are provided based on disease type, diagnosis, treatment, and end user.
The countries covered in this market report are the U.S., Canada, and Mexico in North America, Germany, France, the U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa(MEA), Brazil, Argentina and Rest of South America as part of South America.
North America is expected to dominate the global depression screening market due to the increasing research in depression screening and development.
The U.S. is expected to dominate the North America region due to the rise in healthcare expenditure and the high prevalence of dental diseases seen in the country. Germany is expected to dominate Europe due to the increasing technology and reliability of healthcare services, which also deliver infotainment services. The demand in this region is projected to be driven by a rise in dental diseases with the growing integration of healthcare data with portable devices. China is expected to dominate the Asia-Pacific region due to exponential awareness of cancer diagnostics and consultancy services in the country.
The country section of the report also provides individual market-impacting factors and changes in market regulation that impact the current and future trends of the market. Data points such as downstream and upstream value chain analysis, technical trends, Porter's five forces analysis, and case studies are some pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges due to large or scarce competition from local and domestic brands and the impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Healthcare Infrastructure Growth Installed Base and New Technology Penetration
The global depression screening market also provides you with a detailed market analysis for every country’s growth in healthcare expenditure for capital equipment, installed base of different kind of products for global depression screening market, the impact of technology using lifeline curves, and changes in healthcare regulatory scenarios and their impact on the market. The data is available for the historic period 2015-2020.
Competitive Landscape and Global Depression Screening Market Share Analysis
The global depression screening market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to the market.
Some of the major players operating in the global depression screening market are:
- Johnson & Johnson Services Inc. (U.S.)
- AstraZeneca (U.K.)
- Bristol-Myers Squibb Company (U.S.)
- Lilly (U.S.)
- F. Hoffmann-La Roche Ltd., (Switzerland)
- Novartis AG (Switzerland)
- Otsuka Holdings Co., Ltd. (Japan)
- Pfizer Inc. (U.S.)
- GSK plc (U.K.)
- Janssen Global Services LLC, (Belgium)
- Meiji Holdings Co., Ltd (Japan)
- Abbott (U.S.)
- Jazz Pharmaceuticals Inc. (Ireland)
- AbbVie Inc. (U.S.)
- 3M (U.S.)
- Acadia Pharmaceuticals Inc. (U.S.)
- Medtronic (Ireland)
- Bausch Health Companies Inc. (Canada)
- Merck KGaA (Germany)
SKU-